Drug Type TCR-T Cell therapy |
Synonyms NEOTCRP201 |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bladder Cancer | Preclinical | United States | 21 Jul 2022 | |
| Breast Cancer | Preclinical | United States | 21 Jul 2022 | |
| Colorectal Cancer | Preclinical | United States | 21 Jul 2022 | |
| Head and Neck Neoplasms | Preclinical | United States | 21 Jul 2022 | |
| Lung Cancer | Preclinical | United States | 21 Jul 2022 | |
| Melanoma | Preclinical | United States | 21 Jul 2022 | |
| Ovarian Cancer | Preclinical | United States | 21 Jul 2022 | |
| Prostatic Cancer | Preclinical | United States | 21 Jul 2022 |





